XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.25.3

Financial Instruments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Fair Value Disclosures [Abstract] |
Schedule of Changes in Fair Value of Outstanding Warrant and Tranche Liabilities | The following tables summarize the changes in fair value of our outstanding warrant liabilities, contingent earnout liability, SEPA liability and revenue base redemption liability for the nine months ended September 30, 2025:
Warrant Liabilities |  | Fair Value at December 31, 2024 |  | Change in Unrealized (Gains) Losses |  | Issuances (Settlements) |  | Fair Value at September 30, 2025
Public Warrants - Level 1 |  | $ | 1,927 |  |  | $ | 1,051 |  |  | $ | — |  |  | $ | 2,978 |
Private Placement Warrants - Level 2 |  | 4,872 |  |  | 2,657 |  |  | — |  |  | 7,529 |
Working Capital Warrants - Level 2 |  | 1,100 |  |  | 600 |  |  | — |  |  | 1,700 |
Total |  | $ | 7,899 |  |  | $ | 4,308 |  |  | $ | — |  |  | $ | 12,207 |
Level 3 Liabilities |  | Fair Value at December 31, 2024 |  | Change in Unrealized (Gains) Losses |  | Issuances (Settlements) |  |  |  | Fair Value at September 30, 2025
Contingent earnout liability |  | $ | 7,401 |  |  | $ | (2,404) |  |  | $ | — |  |  |  |  | $ | 4,997 |
SEPA liability |  | $ | 55 |  |  | $ | (55) |  |  | $ | — |  |  |  |  | $ | — |
OrbiMed Warrants liability |  | $ | 362 |  |  | $ | (151) |  |  | $ | 366 |  |  |  |  | $ | 577 |
Revenue base redemption liability |  | $ | 507 |  |  | $ | (5) |  |  | $ | — |  |  |  |  | $ | 502 |
The following tables summarize the changes in fair value of our outstanding warrant liabilities, contingent earnout liability, SEPA liability, and revenue base redemption liability for the nine months ended September 30, 2024:
Warrant Liabilities |  | Fair Value at December 31, 2023 |  | Change in Unrealized (Gains) Losses |  | Issuances (Settlements) |  | Fair Value at September 30, 2024
Public Warrants - Level 1 |  | $ | 9,855 |  |  | $ | 2,982 |  |  | $ | (11,068) |  |  | $ | 1,769 |
Private Placement Warrants - Level 2 |  | 5,871 |  |  | (542) |  |  | (855) |  |  | 4,474 |
Working Capital Warrants - Level 2 |  | 1,190 |  |  | (180) |  |  | — |  |  | 1,010 |
Total |  | $ | 16,916 |  |  | $ | 2,260 |  |  | $ | (11,923) |  |  | $ | 7,253 |
Level 3 Liabilities |  | Fair Value at December 31, 2023 |  | Change in Unrealized (Gains) Losses |  | Issuances (Settlements) |  |  |  | Fair Value at September 30, 2024
Contingent earnout liability |  | $ | 18,632 |  |  | $ | (12,061) |  |  | $ | — |  |  |  |  | $ | 6,571 |
SEPA liability |  | $ | 185 |  |  | $ | 51 |  |  | $ | — |  |  |  |  | $ | 236 |
Initial OrbiMed Warrant liability |  | $ | — |  |  | $ | (488) |  |  | $ | 811 |  |  |  |  | $ | 323 |
Revenue base redemption liability |  | $ | — |  |  | $ | (303) |  |  | $ | 729 |  |  |  |  | $ | 426 |

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration